HIM
PLX icon

Hillsdale Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

Hillsdale Investment Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Buy
+185,711
New +$393K 0.01% 458
2025
Q3 		– Sell
-118,100
Closed -$175K – 716
2025
Q2 		$175K Buy
118,100
+2,000
+2% +$4.09K 0.01% 466
2025
Q1 		$297K Buy
+116,100
New +$277K 0.02% 393

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Hillsdale Investment Management's PLX Position: Q2 2026 in Review

Hillsdale Investment Management opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 185,711 shares worth $433K. The stake represents 0.01% of the portfolio and ranks #458 among its holdings. This is a return to the name: Hillsdale Investment Management previously reported a position in PLX as recently as Q2 2025.

Hillsdale Investment Management first reported a position in PLX in Q1 2025 and has held it in 3 quarters since. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Hillsdale Investment Management held 185,711 shares of Protalix BioTherapeutics worth $433K as of Q2 2026.
  • Protalix BioTherapeutics was a new Hillsdale Investment Management position in Q2 2026.
  • Protalix BioTherapeutics made up 0.01% of Hillsdale Investment Management's portfolio in Q2 2026, its #458 holding.
  • Hillsdale Investment Management first reported a position in Protalix BioTherapeutics in Q1 2025 and has held it in 3 quarters since.
  • 101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.